Get the Stockscreener App
1.56
0.64%
-0.01
After Hours:
1.64
0.08
+5.13%
Acumen Pharmaceuticals Inc stock is traded at $1.56, with a volume of 204.14K.
It is down -0.64% in the last 24 hours and down -10.86% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.57
Open:
$1.59
24h Volume:
204.14K
Relative Volume:
0.70
Market Cap:
$93.72M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.3929
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-9.83%
1M Performance:
-10.86%
6M Performance:
-54.39%
1Y Performance:
-52.58%
1-Day Range:
$1.53
$1.60
1-Week Range:
$1.53
$1.7375
52-Week Range:
$1.53
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.56 | 93.72M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares - MarketBeat
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 - MSN
Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN
Analysts Set Expectations for ABOS FY2025 Earnings - Defense World
Acumen Pharmaceuticals CFO sells shares totaling $56,619 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com - Investing.com Canada
Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC - Defense World
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1% - Defense World
Acumen stock touches 52-week low at $1.54 amid market challenges - MSN
Acumen stock touches 52-week low at $1.54 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian
Acumen's Alzheimer's Drug Shows Promise: Phase 1 Trial Reveals Strong Safety Profile, Plaque Reduction - StockTitan
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Purchased by Geode Capital Management LLC - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Bought by Barclays PLC - Defense World
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock - Investing.com India
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in Stock - MarketBeat
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals’ chief legal officer sells $20,505 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals CEO sells shares worth $87,873 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock - Investing.com
Acumen Pharmaceuticals CEO sells shares worth $87,873 - Investing.com
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock - Investing.com
Reviewing Acumen Pharmaceuticals (NASDAQ:ABOS) & argenx (NASDAQ:ARGX) - Defense World
State Street Corp Has $1.28 Million Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.71 amid market challenges - Investing.com Nigeria
ABOS stock touches 52-week low at $1.71 amid market challenges By Investing.com - Investing.com South Africa
Acumen stock touches 52-week low at $1.9 amid market challenges - Investing.com Australia
The Manufacturers Life Insurance Company Lowers Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
ABOS stock touches 52-week low at $2.08 amid market challenges - Investing.com Australia
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):